Pancreatic Diseases Clinical Trial
Official title:
Flexible Percutaneous Transhepatic Cholangiopancreatoscopy (PTCS) in Complex Pancreaticobiliary Disease
NCT number | NCT04580940 |
Other study ID # | E7160 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | July 27, 2021 |
Est. completion date | January 14, 2023 |
Verified date | November 2023 |
Source | Boston Scientific Corporation |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational [Patient Registry] |
To document the clinical utility of percutaneous cholangiopancreatoscopy using a thin, disposable, flexible endoscope for evaluation and treatment of complex pancreaticobiliary disease in a prospective, multi-center case series
Status | Completed |
Enrollment | 50 |
Est. completion date | January 14, 2023 |
Est. primary completion date | December 14, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Scheduled for a percutaneous transhepatic procedure to access the pancreaticobiliary anatomy that will accommodate passage of SpyGlass™ Discover Digital Catheter per local standard of practice 2. Written informed consent from patient or legally authorized representative of the patient Exclusion Criteria: 1. Contraindication for cholangiopancreatoscopy 2. Subjects with unresolved adverse event(s) associated with prior percutaneous pancreaticobiliary ductal access 3. <18 years of age 4. Potentially vulnerable subjects, including, but not limited to pregnant women |
Country | Name | City | State |
---|---|---|---|
Belgium | Erasme University Hospital | Brussels | |
Canada | Toronto General Hospital, University Health Network | Toronto | Ontario |
Germany | Evangelisches Krakenhaus Düsseldorf | Düsseldorf | |
Hong Kong | Prince of Wales Hospital | Shatin | NewTerritories |
India | Asian Institute of Gastroenterology | Hyderabad | Somajiguda |
Italy | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Roma | |
United States | Virginia Mason Medical Center | Seattle | Washington |
Lead Sponsor | Collaborator |
---|---|
Boston Scientific Corporation |
United States, Belgium, Canada, Germany, Hong Kong, India, Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Achieving clinical intent of procedure as indicated | Physicians will report achieving clinical success by recording the completed procedures compared to procedures planned by 30 days (+/- 3 days) after index PTCS. | 1 month | |
Secondary | Number of Adverse Events | Serious adverse events related to the study device, accessory devices used through the working channel of the SpyGlass™ Discover Digital Catheter or the cholangiopancreatoscopy portion of the PTCS procedure(s). | 1 month | |
Secondary | Technical success | Rate at which SpyGlass™ Discover digital catheter can be advanced to the target lesion or stone(s) and visualize the target | During index procedure | |
Secondary | Procedural Time | Time elapsed between first insertion to last removal of the SpyGlass™ Discover digital catheter | During index procedure | |
Secondary | Number of PTCS procedures | Number of PTCS procedures required to achieve clinical success until the end of follow-up | 1 month | |
Secondary | Endoscopist rating | Endoscopist rating of the following attributes when using SpyGlass™ Discover Digital Catheter compared to marketed reusable scopes Ability to complete the procedure Ability to retroflex Ability to selectively advance into targeted ducts Ability to obtain targeted biopsies Ability to grasp stones Ability to guide lithotripsy Ability to suction Ability to irrigate Ability to advance accessories through scope channel Image quality | During index procedure |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04205058 -
Coffee After Pancreatic Surgery
|
N/A | |
Completed |
NCT02971579 -
A Register on the Quality of ERCP and Training of Endoscopists in Italy
|
||
Not yet recruiting |
NCT01900938 -
Comparison Between Continuous Infusion and Intermittent Bolus Injection of Propofol for Deep Sedation During ERCP
|
N/A | |
Completed |
NCT01427725 -
Special Investigation of LipaCreon on Long-term Use in Patients With Pancreatic Exocrine Insufficiency
|
||
Not yet recruiting |
NCT05954221 -
Red Cell Lysis Buffer Application Versus Conventional Sample Processing in EUS-FNB
|
N/A | |
Enrolling by invitation |
NCT02471170 -
Protocol to Permit the Acquisition of Circulating Tumor Material in Pancreatic Diseases
|
||
Completed |
NCT04705740 -
Influence of the Endoscopists and Endoscopic Retrograde CholangioPanceratography
|
||
Recruiting |
NCT04259580 -
Calgary Registry for Advanced and Therapeutic Endoscopy
|
||
Recruiting |
NCT04291651 -
UCSF PANC Cyst Registry
|
||
Enrolling by invitation |
NCT03234543 -
Remote Ischemic Conditioning in Abdominal Surgery
|
N/A | |
Completed |
NCT02916199 -
Primary Needle Knife Fistulotomy Versus Conventional Cannulation Method
|
N/A | |
Completed |
NCT03717298 -
Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma
|
Phase 2 | |
Recruiting |
NCT03334708 -
A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma
|
||
Recruiting |
NCT05249400 -
Effect of Off-site Assistance on Success Rate of Selective Cannulation During hands-on ERCP Training
|
N/A | |
Recruiting |
NCT05824403 -
PAncreatic Disease Cohort of TOuLouse
|
||
Active, not recruiting |
NCT03269994 -
Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy?
|
Phase 3 | |
Enrolling by invitation |
NCT04329039 -
Somatostatin Analogues With Perioperative Antibiotics Versus Prolonged Antibiotics
|
Phase 2/Phase 3 | |
Completed |
NCT03198871 -
IV Acetaminophen for Post-Operative Pain Management in Enhanced Recovery After Surgery (ERAS) Population
|
Phase 4 | |
Completed |
NCT02337673 -
Screening of Postoperative Pulmonary Complications by Electrical Impedance Tomography
|
||
Completed |
NCT01964430 -
Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)
|
Phase 3 |